Eledon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing medicines for autoimmune diseases, ALS, and organ/cell-based transplants. Its lead product candidate, AT-1501, is a humanized monoclonal antibody targeting CD40 Ligand. It is currently in Phase 2a clinical trials for ALS and Phase 2 trials for type 1 diabetes treatment. Formerly known as Novus Therapeutics, the company changed its name to Eledon Pharmaceuticals in January 2021. Headquartered in Irvine, California.